Recon: Akero drug meets goal in NASH study; Novartis to invest $300M in biologics operations
Regulatory NewsMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy